ALLMedicine™ Von Willebrand Disease Center
Research & Reviews 909 results
https://doi.org/10.1111/ijlh.13907
International Journal of Laboratory Hematology; Favaloro EJ, Mohammed S et. al.
Jun 28th, 2022 - The platelet function analyzer (PFA) is a popular platelet function screening instrument, highly sensitive to von Willebrand disease (VWD) and to aspirin therapy, with moderate sensitivity to defects in platelet function and/or deficiencies in pla...
https://doi.org/10.1111/hae.14609
Haemophilia : the Official Journal of the World Federatio... Champagne PA, Bourassa M et. al.
Jun 26th, 2022 - Persons with inherited bleeding disorders are at a substantial risk of bleeding following dental procedures. To compare the outcomes and use of haemostatic treatment pre- and post-implementation of a standardized protocol for dental procedures at ...
https://doi.org/10.1080/17474086.2022.2074395
Expert Review of Hematology; Jain N, Oldenburg J et. al.
Jun 25th, 2022 - Hemophilia, von Willebrand disease (VWD), and thrombotic thrombocytopenic purpura (TTP) are rare diseases affecting normal hemostasis. Although they differ in their pathogenesis and clinical manifestation, if left undiagnosed and untreated, all th...
https://doi.org/10.1016/j.leukres.2022.106903
Leukemia Research; Rippel N, Tremblay D et. al.
Jun 20th, 2022 - Anagrelide (ANA) is a platelet-specific cytoreductive agent utilized in the guideline-directed management of high-risk essential thrombocythemia. In the context of polycythemia vera (PV), ANA is occasionally employed in clinical practice, although...
https://clinicaltrials.gov/ct2/show/NCT02792205
Jun 10th, 2022 - Von Willebrand Disease (VWD) is defined as an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and ...
Guidelines 4 results
https://doi.org/10.1016/j.jogc.2017.11.036
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Demers C, Derzko C et. al.
Feb 16th, 2018 - The prevalence of bleeding disorders, notably von Willebrand disease (vWD), among adult women with objectively documented menorrhagia is consistently reported to be 10% to 20% and is even higher in adolescents presenting with menorrhagia. Diagnost...
https://doi.org/10.2450/2008.0052-08
Blood Transfusion = Trasfusione Del Sangue; Mannucci PM, Franchini M et. al.
Jun 9th, 2009 - von Willebrand disease (VWD) is the most common hereditary bleeding disorder affecting both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes bleeding of mucous membranes and soft tissu...
https://doi.org/10.1002/ajh.21405
American Journal of Hematology; Nichols WL, Rick ME et. al.
May 6th, 2009 - Von Willebrand factor (VWF) mediates blood platelet adhesion and accumulation at sites of blood vessel injury, and also carries coagulation factor VIII (FVIII) that is important for generating procoagulant activity. Von Willebrand disease (VWD), t...
https://doi.org/10.1111/j.1365-2516.2007.01643.x
Haemophilia : the Official Journal of the World Federatio... Nichols WL, Hultin MB et. al.
Mar 5th, 2008 - von Willebrand disease (VWD) is a commonly encountered inherited bleeding disorder affecting both males and females, causing mucous membrane and skin bleeding symptoms, and bleeding with surgical or other haemostatic challenges. VWD may be disprop...
Drugs 19 results see all →
Clinicaltrials.gov 65 results
https://clinicaltrials.gov/ct2/show/NCT02792205
Jun 10th, 2022 - Von Willebrand Disease (VWD) is defined as an inherited bleeding disorder that is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and ...
https://clinicaltrials.gov/ct2/show/NCT04398628
May 25th, 2022 - This is a longitudinal, natural history observational cohort study being conducted at approximately 150 ATHN-affiliated sites. Participants will be followed for a minimum of 15 years. Harmonized data elements will be collected at time of enrollmen...
https://clinicaltrials.gov/ct2/show/NCT04770935
May 9th, 2022 - Duration of each part of the study for one participant: Total study duration: Up to 57 days. Screening: up to 28 days. Up to 29 days of safety observation following the IV BIVV001 dose administration (this period includes PK sampling up to the fir...
https://clinicaltrials.gov/ct2/show/NCT02932618
Apr 25th, 2022 - The main aim of the study is to check effectiveness, side effects, and tolerability of recombinant von Willebrand Factor (rVWF), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less th...
https://clinicaltrials.gov/ct2/show/NCT03879135
Apr 21st, 2022 - The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants during the first 12 mon...
News 64 results
https://www.mdedge.com/hematology-oncology/article/252066/bleeding-disorders/women-von-willebrand-disease-managing
Heidi Splete
Feb 23rd, 2022 - Hormonal therapy remains the most effective strategy for managing heavy menstrual bleeding in women with von Willebrand disease, based on data from one of three systematic reviews. Women with von Willebrand disease (VWD) experience many obstetric.
https://www.mdedge.com/hematology-oncology/article/244070/bleeding-disorders/infusion-shown-effective-acquired-von
Mark S. Lesney, PhD
Aug 10th, 2021 - Acquired von Willebrand disease (aVWD) is a rare and serious condition associated with lymphoproliferative disorders, malignancy, autoimmune disorders, and cardiovascular disease. It is most commonly caused by monoclonal gammopathy of undetermined.
https://www.mdedge.com/hematology-oncology/article/241963/bleeding-disorders/novel-molecule-prolongs-half-life-bleeding
Neil Osterweil
Jun 23rd, 2021 - A novel therapeutic approach using aptamers – short single strands of DNA or RNA designed to selectively bind to a target – shows promise for treating von Willebrand Disease (VWD), and other congenital bleed disorders such as hemophilia A, investi.
https://www.mdedge.com/hematology-oncology/article/241277/bleeding-disorders/first-year-life-sees-initial-bleeding-episodes
Mark S. Lesney, PhD
Jun 9th, 2021 - To remedy a lack of data on infants and toddlers with von Willebrand disease (VWD), researchers examined data on patients collected from the U. S.
https://www.mdedge.com/hematology-oncology/article/236987/bleeding-disorders/type-3-von-willebrand-rare-serious-bleeding
Neil Osterweil
Mar 10th, 2021 - Type 3 von Willebrand disease (VWD) is rare, but this form of the disease is associated with severe bleeding, particularly in muscles and joints, a bleeding disorders expert said. “There’s a virtually complete deficiency in von Willebrand factor [.